Dapagliflozin impurity

• CAT Number: I017952
• CAS Number: 960404-86-8
• Molecular Formula: C₂₁H₂₅ClO₇
• Molecular Weight: 424.87
• Purity: ≥95%
• Target: SGLT
• IUPAC Name: (2S,3R,4S,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
• InChI: InChI=1S/C21H25ClO7/c1-2-28-15-6-3-12(4-7-15)9-13-10-14(5-8-16(13)22)21(27)20(26)19(25)18(24)17(11-23)29-21/h3-8,10,17-20,23-27H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
• InChIKey: KYDGWGYAUCJZDV-ADAARDCZSA-N
• SMILES: CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@]3([C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)Cl

Dapagliflozin Impurity(CAT; I017952) refers to chemical byproducts or degradation products associated with the synthesis or stability of dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor used in diabetes research and therapy. These impurities are critical for analytical method development, quality control, and regulatory compliance in pharmaceutical manufacturing. Studying dapagliflozin impurities enables researchers to understand degradation pathways, ensure drug purity, and enhance formulation stability. These compounds are often employed in toxicological studies to assess their safety profiles and to meet stringent regulatory requirements for drug development and approval. Dapagliflozin Impurities are essential tools for advancing pharmaceutical quality assurance and safety.

Reference

[1]. Kasichayanula S, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011 Jan;13(1):47-54.